Heterogeneity‐based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report

Osimertinib is a novel, irreversible, mutant‐selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR mutations and the EGFR T790 mutation. Here, we report a woman with EGFR‐mutated lung adenocarcinoma who, after 23‐month treatment with gefitinib, developed the EGFR...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Thorac Cancer
Päätekijät: Liu, Yutao, Hao, Xuezhi, Hu, Xingsheng, Li, Junling, Wang, Yan, Wang, Hongyu, Xing, Puyuan, Li, Weihua, Ying, Jianming, Han, Xiaohong, Shi, Yuankai
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons Australia, Ltd 2018
Aiheet:
Case Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5879057/
https://ncbi.nlm.nih.gov/pubmed/29411527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12596
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia